ITRM20010210A0 - Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt - Google Patents

Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt

Info

Publication number
ITRM20010210A0
ITRM20010210A0 IT2001RM000210A ITRM20010210A ITRM20010210A0 IT RM20010210 A0 ITRM20010210 A0 IT RM20010210A0 IT 2001RM000210 A IT2001RM000210 A IT 2001RM000210A IT RM20010210 A ITRM20010210 A IT RM20010210A IT RM20010210 A0 ITRM20010210 A0 IT RM20010210A0
Authority
IT
Italy
Prior art keywords
hiv
cancers
therapy
diseases
immunodeficiency virus
Prior art date
Application number
IT2001RM000210A
Other languages
English (en)
Inventor
Barbara Ensoli
Original Assignee
Ist Superiore Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita
Priority to IT2001RM000210A priority Critical patent/ITRM20010210A1/it
Publication of ITRM20010210A0 publication Critical patent/ITRM20010210A0/it
Priority to HU0401199A priority patent/HUP0401199A2/hu
Priority to SK1421-2003A priority patent/SK14212003A3/sk
Priority to EA200301130A priority patent/EA006678B1/ru
Priority to US10/549,958 priority patent/US20060088545A1/en
Priority to MXPA03010380A priority patent/MXPA03010380A/es
Priority to CZ20033113A priority patent/CZ20033113A3/cs
Priority to EEP200300507A priority patent/EE200300507A/xx
Priority to PCT/EP2002/004303 priority patent/WO2002087583A2/en
Priority to CA002447748A priority patent/CA2447748A1/en
Priority to APAP/P/2003/002901A priority patent/AP2003002901A0/en
Priority to EP02766632A priority patent/EP1401447A2/en
Priority to CNA028121260A priority patent/CN1700916A/zh
Publication of ITRM20010210A1 publication Critical patent/ITRM20010210A1/it
Priority to BG108368A priority patent/BG108368A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT2001RM000210A 2001-04-18 2001-04-18 Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt ITRM20010210A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT2001RM000210A ITRM20010210A1 (it) 2001-04-18 2001-04-18 Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt
CNA028121260A CN1700916A (zh) 2001-04-18 2002-04-18 Hiv蛋白酶抑制剂在阻断细胞迁移和/或侵袭、组织浸润和水肿形成中的用途
CZ20033113A CZ20033113A3 (cs) 2001-04-18 2002-04-18 Farmaceutický prostředek obsahující inhibitory proteázy
PCT/EP2002/004303 WO2002087583A2 (en) 2001-04-18 2002-04-18 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
EA200301130A EA006678B1 (ru) 2001-04-18 2002-04-18 Применение ингибиторов протеазы вируса иммунодефицита человека (вич) для блокирования миграции клеток и/или инвазии, инфильтрации тканей и отека при лечении связанных с этим заболеваний
US10/549,958 US20060088545A1 (en) 2001-04-18 2002-04-18 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therary of diseases associated therewith
MXPA03010380A MXPA03010380A (es) 2001-04-18 2002-04-18 Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema.
HU0401199A HUP0401199A2 (hu) 2001-04-18 2002-04-18 A humán immundeficiencia vírus (HIV) proteáz inhibitorainak alkalmazása sejtvándorlás és/vagy sejtinvázió, szöveti infiltráció és ödéma blokkolására az ehhez kapcsolódó betegségek terápiájára
EEP200300507A EE200300507A (et) 2001-04-18 2002-04-18 HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks
SK1421-2003A SK14212003A3 (sk) 2001-04-18 2002-04-18 Použitie inhibítorov proteázy ľudského vírusu imunitnej nedostatočnosti
CA002447748A CA2447748A1 (en) 2001-04-18 2002-04-18 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
APAP/P/2003/002901A AP2003002901A0 (en) 2001-04-18 2002-04-18 Use of HIV-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
EP02766632A EP1401447A2 (en) 2001-04-18 2002-04-18 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith
BG108368A BG108368A (bg) 2001-04-18 2003-11-18 Използване на инхибитори на hiv-протеаза за блокиране на клетъчна миграция и/или инвазия, инфилтрация на тъкан и формация на оток

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000210A ITRM20010210A1 (it) 2001-04-18 2001-04-18 Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt

Publications (2)

Publication Number Publication Date
ITRM20010210A0 true ITRM20010210A0 (it) 2001-04-18
ITRM20010210A1 ITRM20010210A1 (it) 2002-10-18

Family

ID=11455472

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000210A ITRM20010210A1 (it) 2001-04-18 2001-04-18 Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt

Country Status (14)

Country Link
US (1) US20060088545A1 (it)
EP (1) EP1401447A2 (it)
CN (1) CN1700916A (it)
AP (1) AP2003002901A0 (it)
BG (1) BG108368A (it)
CA (1) CA2447748A1 (it)
CZ (1) CZ20033113A3 (it)
EA (1) EA006678B1 (it)
EE (1) EE200300507A (it)
HU (1) HUP0401199A2 (it)
IT (1) ITRM20010210A1 (it)
MX (1) MXPA03010380A (it)
SK (1) SK14212003A3 (it)
WO (1) WO2002087583A2 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051361A1 (en) * 2001-12-14 2003-06-26 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
US7812034B2 (en) * 2003-11-04 2010-10-12 City Of Hope Method of using protease inhibitors for the treatment of liposarcomas
US20090010990A1 (en) * 2007-06-20 2009-01-08 Little Marisa A Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process
US8741924B2 (en) 2010-05-06 2014-06-03 The Feinstein Institute For Medical Research Compounds and methods for treatment of systemic lupus erythematosus
US20130317040A1 (en) * 2010-12-22 2013-11-28 The Feinstein Institute Of Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
WO2000033654A1 (en) * 1998-12-04 2000-06-15 University Of Maryland Biotechnology Institute Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith

Also Published As

Publication number Publication date
WO2002087583A3 (en) 2002-12-19
WO2002087583A2 (en) 2002-11-07
CA2447748A1 (en) 2002-11-07
EE200300507A (et) 2004-02-16
AP2003002901A0 (en) 2003-12-31
SK14212003A3 (sk) 2004-06-08
HUP0401199A2 (hu) 2004-12-28
EA006678B1 (ru) 2006-02-24
EP1401447A2 (en) 2004-03-31
MXPA03010380A (es) 2004-03-16
US20060088545A1 (en) 2006-04-27
BG108368A (bg) 2005-01-31
CZ20033113A3 (cs) 2004-07-14
EA200301130A1 (ru) 2004-04-29
WO2002087583B1 (en) 2003-11-20
ITRM20010210A1 (it) 2002-10-18
CN1700916A (zh) 2005-11-23

Similar Documents

Publication Publication Date Title
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
SE0100901D0 (sv) New composition
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
IS7079A (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
DE60210880D1 (de) Kombiniertes bipolares Zangen- und Schereninstrument
DOP2002000429A (es) Imidazotriazinas
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200300545A (et) 4-(fenüülpiperasinüülmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse ja seedetrakti häirete ravis
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
EE200400028A (et) Ravimpreparaat, selle valmistamise meetod ja selle kasutamine meditsiinis
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
ITMI20011057A0 (it) Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
EA200400399A1 (ru) Способы лечения легочных заболеваний
ITRM20010210A0 (it) Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt
AU2001291225A1 (en) Analysis of hiv-1 coreceptor use in the clinical care of hiv-1-infected patients
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
ITMI20010100U1 (it) Chiodo endomidollare per l'osteosintesi delle fratture troncanterichedel femore
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE60203934D1 (de) Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonisten
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.